{
    "organizations": [],
    "uuid": "6d1c7e2e50d668ee37ee679135e73795998567f0",
    "author": "",
    "url": "https://www.reuters.com/article/brief-incyte-merck-provide-update-on-pha/brief-incyte-merck-provide-update-on-phase-3-study-idUSASC09V4M",
    "ord_in_thread": 0,
    "title": "BRIEF-Incyte, Merck Provide Update On Phase 3 Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 6, 2018 / 11:40 AM / Updated 5 minutes ago BRIEF-Incyte, Merck Provide Update On Phase 3 Study Reuters Staff 1 Min Read \nApril 6 (Reuters) - Incyte Corp: \n* INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA \n* INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA \n* STUDY’S SECOND PRIMARY ENDPOINT OF OVERALL SURVIVAL ALSO IS NOT EXPECTED TO REACH STATISTICAL SIGNIFICANCE \n* BASED ON RESULTS, AND AT RECOMMENDATION OF EDMC, PHASE 3 STUDY WILL BE STOPPED \n* 252 WAS CONSISTENT WITH THAT OBSERVED IN STUDIES OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA \n* 252 STUDY EVALUATING EPACADOSTAT WITH KEYTRUDA DETERMINED STUDY DID NOT MEET PRIMARY ENDPOINT Source text for Eikon: Further company coverage:",
    "published": "2018-04-06T14:39:00.000+03:00",
    "crawled": "2018-04-06T15:00:14.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "updated",
        "minute",
        "ago",
        "merck",
        "provide",
        "update",
        "phase",
        "study",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "incyte",
        "corp",
        "incyte",
        "merck",
        "provide",
        "update",
        "phase",
        "study",
        "epacadostat",
        "combination",
        "pembrolizumab",
        "patient",
        "unresectable",
        "metastatic",
        "melanoma",
        "incyte",
        "merck",
        "provide",
        "update",
        "phase",
        "study",
        "epacadostat",
        "combination",
        "pembrolizumab",
        "patient",
        "unresectable",
        "metastatic",
        "melanoma",
        "study",
        "second",
        "primary",
        "endpoint",
        "overall",
        "survival",
        "also",
        "expected",
        "reach",
        "statistical",
        "significance",
        "based",
        "result",
        "recommendation",
        "edmc",
        "phase",
        "study",
        "stopped",
        "consistent",
        "observed",
        "study",
        "epacadostat",
        "combination",
        "keytruda",
        "study",
        "evaluating",
        "epacadostat",
        "keytruda",
        "determined",
        "study",
        "meet",
        "primary",
        "endpoint",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}